Jubilant Ingrevia (JUBLINGREA) Stock Overview
Engages in life science products and solutions in India, the United States, Europe, China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for JUBLINGREA from our risk checks.
JUBLINGREA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jubilant Ingrevia Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹608.20 |
| 52 Week High | ₹851.80 |
| 52 Week Low | ₹537.30 |
| Beta | 0.28 |
| 1 Month Change | -5.88% |
| 3 Month Change | 6.14% |
| 1 Year Change | -20.58% |
| 3 Year Change | 44.57% |
| 5 Year Change | 11.47% |
| Change since IPO | 126.35% |
Recent News & Updates
Narrative Update • Jun 15
JUBLINGREA: Upcoming Board Meeting And Dividend Decision Will Support Long Term Earnings Visibility
Analysts keep the Jubilant Ingrevia price target steady at ₹1,150, citing only marginal updates to the discount rate, revenue growth, profit margin, and future P/E assumptions that are not large enough to shift their overall view. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 a.m. IST to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • Jun 01
JUBLINGREA: Upcoming Board Decisions Will Support Confidence In Long Term Earnings Visibility
Analysts have lifted their price target on Jubilant Ingrevia from ₹1,100 to ₹1,150 as they now apply a higher future P/E multiple, along with slightly lower assumptions for the discount rate, revenue growth and profit margin. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 IST to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).
Narrative Update • May 06
JUBLINGREA: Upcoming Meetings Will Highlight Risks To Current Optimism
Analysts have kept their price target for Jubilant Ingrevia steady at ₹657. Updated assumptions reflect slightly different views on discount rate, revenue growth, profit margin and future P/E to support this unchanged valuation.Recent updates
Narrative Update • Jun 15
JUBLINGREA: Upcoming Board Meeting And Dividend Decision Will Support Long Term Earnings Visibility
Analysts keep the Jubilant Ingrevia price target steady at ₹1,150, citing only marginal updates to the discount rate, revenue growth, profit margin, and future P/E assumptions that are not large enough to shift their overall view. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 a.m. IST to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative Update • Jun 01
JUBLINGREA: Upcoming Board Decisions Will Support Confidence In Long Term Earnings Visibility
Analysts have lifted their price target on Jubilant Ingrevia from ₹1,100 to ₹1,150 as they now apply a higher future P/E multiple, along with slightly lower assumptions for the discount rate, revenue growth and profit margin. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 IST to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Narrative Update • May 06
JUBLINGREA: Upcoming Meetings Will Highlight Risks To Current Optimism
Analysts have kept their price target for Jubilant Ingrevia steady at ₹657. Updated assumptions reflect slightly different views on discount rate, revenue growth, profit margin and future P/E to support this unchanged valuation.Narrative Update • Apr 21
JUBLINGREA: Upcoming Postal Ballot Will Support Confidence In Long Term Earnings Visibility
Analysts keep the fair value estimate for Jubilant Ingrevia steady at ₹1,100, with only small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this unchanged price target. What's in the News Jubilant Ingrevia has scheduled a Special or Extraordinary Shareholders Meeting for April 4, 2026, to be conducted via postal ballot in India (Key Developments).Narrative Update • Apr 07
JUBLINGREA: Upcoming Meetings Will Strengthen Confidence In Long Term Earnings Visibility
Analysts have kept the Jubilant Ingrevia price target unchanged at ₹1,100, with slight tweaks to model inputs such as discount rate, revenue growth, profit margin and future P/E, which underpin the refreshed view. What's in the News Board meeting scheduled for Feb 04, 2026 to consider unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025, which could provide fresh visibility on recent operating trends (Key Developments).Narrative Update • Mar 24
JUBLINGREA: Upcoming Board Meeting Will Clarify Bullish Medium Term Outlook
Analysts have maintained the fair value for Jubilant Ingrevia at ₹657. A slightly lower discount rate, marginally higher assumptions for revenue growth and profit margins, and a modestly reduced future P/E expectation together shape the updated price target view.Narrative Update • Mar 09
JUBLINGREA: Future Board Decisions Will Support Stronger Long Term Earnings Visibility
Analysts have trimmed their price target on Jubilant Ingrevia from ₹1,250 to ₹1,100. This reflects updated assumptions in their models around slightly softer revenue growth, lower profit margins and a higher future P/E multiple.Narrative Update • Feb 23
JUBLINGREA: Upcoming Results And Refined Assumptions Will Shape Medium Term Outlook
Analysts have kept their fair value estimate for Jubilant Ingrevia unchanged at ₹657, while slightly adjusting their assumptions around discount rate, revenue growth, profit margin and future P/E to reflect a more balanced risk and earnings profile. What's in the News Board meeting scheduled on February 4, 2026, to consider the unaudited standalone financial results for the quarter ended December 31, 2025 (company filing).Narrative Update • Feb 09
JUBLINGREA: Upcoming Results And Assumption Tweaks Will Shape Medium Term Outlook
Narrative Update The analyst price target for Jubilant Ingrevia has been revised from ₹695 to ₹657 as analysts factor in updated assumptions around the discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Board meeting scheduled for Feb 04, 2026 to consider Unaudited Standalone Financial Results for the quarter ended Dec 31, 2025 (company filing).Analysis Article • Feb 07
Earnings Miss: Jubilant Ingrevia Limited Missed EPS By 17% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) filed its quarterly result this time...Analysis Article • Feb 04
Investors Still Waiting For A Pull Back In Jubilant Ingrevia Limited (NSE:JUBLINGREA)
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a...Narrative Update • Jan 25
JUBLINGREA: Upcoming Board Review And Steady Margins Will Shape Medium Term Outlook
Analysts have maintained their fair value estimate for Jubilant Ingrevia at ₹695.00, making only minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. This reflects a largely unchanged view on the stock's potential.Narrative Update • Jan 10
JUBLINGREA: Upcoming Board Review And Margins Will Shape Medium Term Outlook
Analysts have kept their price target for Jubilant Ingrevia steady at ₹695. This reflects only marginal tweaks to assumptions on discount rate, revenue growth, profit margins and expected future P/E rather than a material shift in their overall view.Analysis Article • Jan 06
These 4 Measures Indicate That Jubilant Ingrevia (NSE:JUBLINGREA) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Dec 26
JUBLINGREA: Upcoming Results And Margins Will Shape Balanced Medium Term Outlook
Analysts have made a modest upward revision to their price target for Jubilant Ingrevia to ₹695.00, reflecting slightly higher long term valuation multiples despite marginal trims to revenue growth and profit margin assumptions. What's in the News Board meeting scheduled for October 27, 2025, at 13:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value: Unchanged at ₹695.00 per share.Narrative Update • Dec 12
JUBLINGREA: Medium Term Margins And Growth Will Shape Fair Outlook
Analysts have reduced their price target for Jubilant Ingrevia to ₹695 from ₹743, reflecting more conservative assumptions on medium-term revenue growth and profit margins, despite a slightly lower discount rate and higher expected future valuation multiples. What's in the News Board meeting scheduled for October 27, 2025, at 13:30 IST to review the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).
Narrative Update • Nov 27
JUBLINGREA: Solid Revenue Outlook And Profitable Operations Will Boost Future Upside
Analysts have maintained their price target for Jubilant Ingrevia at ₹987.75, citing stable revenue growth prospects and a largely unchanged outlook on profitability and valuation metrics. What's in the News A board meeting is scheduled for October 27, 2025 at 1:30 PM IST to consider the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Narrative Update • Nov 13
JUBLINGREA: Strong Profit Margins And Business Outlook Will Drive Share Upside
Analysts have slightly lowered their price target for Jubilant Ingrevia from ₹999.75 to ₹987.75. This change is based on minor adjustments in their valuation models, reflecting updated growth and profitability assumptions.Analysis Article • Nov 07
Jubilant Ingrevia (NSE:JUBLINGREA) Shareholders Will Want The ROCE Trajectory To Continue
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Narrative Update • Oct 28
Improved Margins And Board Meeting Will Shape Export Opportunity Outlook
The analyst price target for Jubilant Ingrevia has been raised from ₹944.75 to ₹999.75. This reflects an improved margin outlook and a modestly higher profit forecast, according to analysts.Analysis Article • Oct 17
Are Investors Undervaluing Jubilant Ingrevia Limited (NSE:JUBLINGREA) By 38%?
Key Insights The projected fair value for Jubilant Ingrevia is ₹1,143 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Sep 20
The Price Is Right For Jubilant Ingrevia Limited (NSE:JUBLINGREA)
With a price-to-earnings (or "P/E") ratio of 38.4x Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) may be sending bearish...Analysis Article • Jul 03
We Like These Underlying Return On Capital Trends At Jubilant Ingrevia (NSE:JUBLINGREA)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Analysis Article • May 16
Jubilant Ingrevia Limited (NSE:JUBLINGREA) Analysts Are Pretty Bullish On The Stock After Recent Results
Last week saw the newest yearly earnings release from Jubilant Ingrevia Limited ( NSE:JUBLINGREA ), an important...Analysis Article • Apr 22
Jubilant Ingrevia Limited's (NSE:JUBLINGREA) Share Price Matching Investor Opinion
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 51.7x might make it look like a...
New Narrative • Feb 17
International Expansion And New Vitamin B3 Facility Will Boost Presence In High-Value Products
Specialty Chemicals and Nutrition & Health segments are poised for growth, boosting revenue and margins through high-margin chemicals and vitamin B3 production.Analysis Article • Feb 01
Jubilant Ingrevia (NSE:JUBLINGREA) Is Due To Pay A Dividend Of ₹2.50
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) will pay a dividend of ₹2.50 on the 26th of February. Based on this...Analysis Article • Jan 31
Results: Jubilant Ingrevia Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest quarterly results, which makes it a good...Analysis Article • Dec 18
Is Jubilant Ingrevia (NSE:JUBLINGREA) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 11
We Think Jubilant Ingrevia (NSE:JUBLINGREA) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Aug 14
Jubilant Ingrevia (NSE:JUBLINGREA) Is Reinvesting At Lower Rates Of Return
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Analysis Article • Jul 19
Jubilant Ingrevia Limited Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week released its latest quarterly, and things did...Analysis Article • Apr 13
Earnings Tell The Story For Jubilant Ingrevia Limited (NSE:JUBLINGREA) As Its Stock Soars 29%
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) shares have had a really impressive month, gaining 29% after a shaky...Analysis Article • Feb 02
Jubilant Ingrevia Limited Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next
Last week, you might have seen that Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) released its quarterly result to the...Analysis Article • Feb 01
A Look At The Fair Value Of Jubilant Ingrevia Limited (NSE:JUBLINGREA)
Key Insights Jubilant Ingrevia's estimated fair value is ₹545 based on 2 Stage Free Cash Flow to Equity With ₹438 share...Analysis Article • Oct 19
Returns At Jubilant Ingrevia (NSE:JUBLINGREA) Are On The Way Up
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Analysis Article • Jun 08
Market Cool On Jubilant Ingrevia Limited's (NSE:JUBLINGREA) Earnings
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 21.9x might make it look like a...Shareholder Returns
| JUBLINGREA | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -3.4% | -2.2% | -1.5% |
| 1Y | -20.6% | -6.8% | -2.9% |
Return vs Industry: JUBLINGREA underperformed the Indian Chemicals industry which returned -6.8% over the past year.
Return vs Market: JUBLINGREA underperformed the Indian Market which returned -2.9% over the past year.
Price Volatility
| JUBLINGREA volatility | |
|---|---|
| JUBLINGREA Average Weekly Movement | 5.0% |
| Chemicals Industry Average Movement | 6.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: JUBLINGREA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: JUBLINGREA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 2,139 | Deepak Jain | jubilantingrevia.com |
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions.
Jubilant Ingrevia Limited Fundamentals Summary
| JUBLINGREA fundamental statistics | |
|---|---|
| Market cap | ₹96.61b |
| Earnings (TTM) | ₹2.78b |
| Revenue (TTM) | ₹43.88b |
34.6x
P/E Ratio2.2x
P/S RatioIs JUBLINGREA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JUBLINGREA income statement (TTM) | |
|---|---|
| Revenue | ₹43.88b |
| Cost of Revenue | ₹27.13b |
| Gross Profit | ₹16.75b |
| Other Expenses | ₹13.98b |
| Earnings | ₹2.78b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 17.58 |
| Gross Margin | 38.18% |
| Net Profit Margin | 6.33% |
| Debt/Equity Ratio | 25.0% |
How did JUBLINGREA perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield28%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 11:54 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jubilant Ingrevia Limited is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| null null | Asian Markets Securities Private Limited |